Cargando…

Analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus in kidney transplant recipients

BACKGROUND: Therapeutic drug monitoring (TDM) of tacrolimus, based on blood concentrations, shows an imperfect correlation with the occurrence of rejection. Here, we tested whether measuring NFATc1 amplification, a member of the calcineurin pathway, is suitable for TDM of tacrolimus. MATERIALS AND M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kannegieter, Nynke M., Hesselink, Dennis A., Dieterich, Marjolein, de Graav, Gretchen N., Kraaijeveld, Rens, Baan, Carla C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056039/ https://www.ncbi.nlm.nih.gov/pubmed/30036394 http://dx.doi.org/10.1371/journal.pone.0201113

Ejemplares similares

Differential T Cell Signaling Pathway Activation by Tacrolimus and Belatacept after Kidney Transplantation: Post Hoc Analysis of a Randomised-Controlled Trial
por: Kannegieter, Nynke M., et al.
Publicado: (2017)

The Effect of Tacrolimus and Mycophenolic Acid on CD14+ Monocyte Activation and Function
por: Kannegieter, Nynke M., et al.
Publicado: (2017)

Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells
por: de Graav, Gretchen N., et al.
Publicado: (2016)

Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation
por: de Graav, Gretchen N., et al.
Publicado: (2017)

Improved Glucose Tolerance in a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To Belatacept: A Case Report and Review of Potential Mechanisms
por: de Graav, Gretchen N., et al.
Publicado: (2018)

Immune Subsets From Ficoll Density Gradient Separation in Kidney Transplant Recipients
por: Udomkarnjananun, Suwasin, et al.
Publicado: (2022)

Tacrolimus Inhibits NF-κB Activation in Peripheral Human T Cells
por: Vafadari, Ramin, et al.
Publicado: (2013)

Response: Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation
por: Baan, Carla C., et al.
Publicado: (2018)

High Tacrolimus Intrapatient Variability and Subtherapeutic Immunosuppression are Associated With Adverse Kidney Transplant Outcomes
por: Mendoza Rojas, Aleixandra, et al.
Publicado: (2022)

Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients
por: Francke, Marith I., et al.
Publicado: (2020)

Targeting the Monocyte–Macrophage Lineage in Solid Organ Transplantation
por: van den Bosch, Thierry P. P., et al.
Publicado: (2017)

A Population Pharmacokinetic Model of Whole-Blood and Intracellular Tacrolimus in Kidney Transplant Recipients
por: Franken, Linda G., et al.
Publicado: (2022)

Characterization of donor and recipient CD8+ tissue-resident memory T cells in transplant nephrectomies
por: de Leur, Kitty, et al.
Publicado: (2019)

T Follicular Helper Cells in Transplantation: The Target to Attenuate Antibody-Mediated Allogeneic Responses?
por: Baan, Carla C., et al.
Publicado: (2014)

Immunomics of Renal Allograft Acute T Cell-Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients
por: van der Zwan, Marieke, et al.
Publicado: (2018)

Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation
por: van der Zwan, Marieke, et al.
Publicado: (2017)

Immunosuppression Has Long-Lasting Effects on Circulating Follicular Regulatory T Cells in Kidney Transplant Recipients
por: Niu, Qian, et al.
Publicado: (2020)

Costimulation Blockade in Kidney Transplant Recipients
por: van der Zwan, Marieke, et al.
Publicado: (2019)

Phospho-specific flow cytometry for pharmacodynamic monitoring of immunosuppressive therapy in transplantation
por: Baan, Carla, et al.
Publicado: (2012)

Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients
por: Francke, M. I., et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation
por: Yu, Meng, et al.
Publicado: (2018)

Direct detection of circulating donor-derived extracellular vesicles in kidney transplant recipients
por: Woud, Wouter W., et al.
Publicado: (2022)

A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients
por: Bunthof, Kim L. W., et al.
Publicado: (2021)

Tacrolimus Monotherapy is Safe in Immunologically Low-Risk Kidney Transplant Recipients: A Randomized-Controlled Pilot Study
por: de Weerd, Annelies E., et al.
Publicado: (2022)

Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics
por: Brunet, Mercè, et al.
Publicado: (2022)

Pharmacogenetic—Whole blood and intracellular pharmacokinetic—Pharmacodynamic (PG-PK(2)-PD) relationship of tacrolimus in liver transplant recipients
por: Tron, Camille, et al.
Publicado: (2020)

Monitoring the Intracellular Tacrolimus Concentration in Kidney Transplant Recipients with Stable Graft Function
por: Han, Seung Seok, et al.
Publicado: (2016)

Axonal Protection by Tacrolimus with Inhibition of NFATc1 in TNF-Induced Optic Nerve Degeneration
por: Tsukahara, Chihiro, et al.
Publicado: (2019)

Tacrolimus trough levels in kidney transplant recipients
por: Hwang, Young Hui, et al.
Publicado: (2021)

Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose
por: Andrews, Louise M., et al.
Publicado: (2017)

Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1
por: Kawahara, Takashi, et al.
Publicado: (2015)

Immunological Monitoring of Renal Transplant Recipients to Predict Acute Allograft Rejection Following the Discontinuation of Tacrolimus
por: Kreijveld, Ellen, et al.
Publicado: (2008)

Switching Stable Kidney Transplant Recipients to a Generic Tacrolimus Is Feasible and Safe, but It Must Be Monitored
por: González, Fernando, et al.
Publicado: (2017)

Clinical Pharmacokinetics of Tacrolimus in Iranian Liver Transplant Recipients
por: Nasiri-Toosi, Zahra, et al.
Publicado: (2014)

Gout Due to Tacrolimus in a Liver Transplant Recipient
por: Afridi, Summia Matin, et al.
Publicado: (2019)

A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients
por: Alloway, R R, et al.
Publicado: (2012)

Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation
por: Fontova, Pere, et al.
Publicado: (2021)

Urinary Extracellular Vesicles Are a Novel Tool to Monitor Allograft Function in Kidney Transplantation: A Systematic Review
por: Wu, Liang, et al.
Publicado: (2021)

Tacrolimus ameliorates tubulointerstitial inflammation in diabetic nephropathy via inhibiting the NFATc1/TRPC6 pathway
por: Zhang, Shumin, et al.
Publicado: (2020)

pERK-dependent defective TCR-mediated activation of CD4(+) T cells in end-stage renal disease patients
por: Huang, Ling, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2md4ede6tblvt64qpern8obc68